177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Neuroendocrine Tumors Clinical Trial

Official title:

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01237457
• Other study ID #: 78,256
• Status: Completed
• Phase: Phase 2
• Start date: October 27, 2010
• Est. completion date: July 25, 2017

Study information

• Verified date: March 2023
• Source: Excel Diagnostics and Nuclear Oncology Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II treatment protocol evaluating 177Lu-DOTATATE therapy for somatostatin receptor-expressing cancers including, but not limited to, those arising from the neural crest and involving such organs as the lungs, breast, gastrointestinal tract, skin, and endocrine (examples: pheochromocytoma, medullary carcinoma of the thyroid, non-radioiodine avid differentiated thyroid cancer, melanoma, renal cell, Merkel cell, paraganglioma, small cell lung, Carcinoid, and pancreatic islet cell malignancies).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: July 25, 2017
• Est. primary completion date: November 17, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with biopsy proven Gastroenteropancreatic (GEP tumors including bronchial carcinoids)

• Presence of somatostatin-receptors on the known tumor lesions demonstrated by OctreoScan within 6 months of the first dose of radiolabelled octreotate therapy. The uptake on the OctreoScan should be at least as high as normal liver uptake on planar imaging.

• Life Expectancy greater than 12 weeks.

• Serum creatinine = 150 µmol/liter or 1.7 mg/dL and a measured creatinine clearance (or measured GFR using plasma clearance methods, not gamma camera based) of = 50ML/min.

• Hemoglobin (Hgb) concentration = 5.5 mmol/L (= 8.9 g/dL); WBC = 2*109/L (2000/mm3); platelets = 100*109/L (100*103/mm3).

• Total Bilirubin = 3X UNL.

• Serum Albumin > 30g/L or serum albumin = 30g/L but normal prothrombin time.

• All patients must have a Karnofsky performance status of at least 60%

• Patients must be greater than 18 years of age. Patients younger than 18 years will be presented to FDA for compassionate use on a case by case basis

Exclusion Criteria:

• Possible surgery with curative intent.

• Surgery, radiotherapy, chemotherapy or other investigational therapy within 3 months of the start of therapy.

• Patients with known brain metastases unless these metastases have been treated and stabilized for at least 6 months prior to study start. Patients with a history of brain metastases must have a head CT with contrast to document stable disease prior to study start.

• Uncontrolled congestive heart failure.

• Any subject who is taking concomitant medications which decrease renal function (such as aminoglycoside antibiotics).

• Any subject receiving therapy with somatostatin analogues, unless the dose has been stable for at least 3 months prior to the first cycle in this study and the disease status during these 4 months has been documented by modified RECISTS criteria as described in this study

• Any subject receiving therapy with short acting somatostatin analogues in whom these analogues cannot be interrupted for 12 hours before and 12 hours after the administration of the radio labelled somatostatin analogues, or any subject who receives therapy with long-acting somatostatin analogues in whom these analogues cannot be interrupted for at least 6 weeks before the administration of the radio labeled somatostatin analogues, unless the uptake on the Octreoscan during continued somatostatin analogue medication is at least as high as normal liver uptake on planar imaging.

• In patients with unusual hematological parameters, including an increased MCV (>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up.

• Subjects with another significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study.

• Prior radiation therapy to more than 25% of the bone marrow.

• Female patients who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 60 days (10 half lives of 177Lu after the last treatment, or male patients who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 60 days after the last treatment

Related Conditions & MeSH terms

• Neoplasms
• Neuroendocrine Tumors

Intervention

Drug:
• 177Lu-DOTATATE
Patients will receive 200mCi dose of 177Lu Dotatate

Locations

Country	Name	City	State
United States	Excel Diagnostics and Nuclear Oncology Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Ebrahim S Delpassand	Excel Diagnostics and Nuclear Oncology Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free survival	Overall response will be determined by Progression Free Survival (PFS). PFS will be calculated as a function of time from start of therapy to time of overall disease progression. Patients will be censored at the date of last contact	one year after completion of last treatment cycle
Secondary	Dose limiting toxicity	Patients will be monitored for dose toxicity according to NCI guidelines	one year after completion of the fourth cycle of treatment